Search for: "ASTRAZENECA LP"
Results 81 - 100
of 138
Sorted by Relevance
|
Sort by Date
10 Feb 2010, 4:47 pm
(Patent Docs) Colmetec (Olmesartan medoxomil, hydrochlorothiazide) – France: Cour d’appel de Paris say ‘non’ to olmesartan medoxomil and hydrochlorothiazide combination SPC: Daiichi Sankyo Company v INPI (SPC Blog) Crestor (Rosuvastatin) – US: Generic drug makers, Teva, Apotex and others seek to remove AstraZeneca LP as party in Crestor suit (Patent Docs) Differin (Adapalene) – US: Patent infringement complaint following a Paragraph IV… [read post]
15 Dec 2011, 10:17 am
AstraZeneca Pharmaceuticals LP, No. 3:11-cv-04001-JAP-TJB, slip op. [read post]
27 May 2010, 3:20 am
AstraZeneca Pharmaceuticals LP et al. [read post]
25 Mar 2016, 3:16 pm
AstraZeneca Pharm. [read post]
10 Sep 2012, 7:28 pm
In July, after a court battle with FDA that started around mid-March when AstraZeneca Pharmaceuticals LP (“AstraZeneca”) sought to enjoin FDA from granting final ANDA approvals for generic SEROQUEL following FDA’s denial (without comment) of two citizen petitions AstraZeneca submitted to FDA last year concerning labeling carve-out issues, the U.S. [read post]
11 Nov 2017, 11:00 am
See AstraZeneca LP v. [read post]
28 Jul 2010, 12:06 am
(Patent Docs) Crestor (Rosuvastatin) – US: Patent infringement complaint following amended ANDA filing: AstraZeneca Pharmaceuticals LP et al. v. [read post]
16 Apr 2012, 1:29 am
District Court are Motions for Summary Judgment filed by FDA and AstraZeneca Pharmaceuticals LP (here and here) concerning FDA’s approval of ANDAs for generic versions of SEROQUEL (quetiapine fumarate) Tablets and the Agency’s decision, discussed in a March 27, 2012 Letter Decision, concerning the scope and applicability of 3-year marketing exclusivity in that case. [read post]
30 Jun 2010, 5:52 am
(Docket Report) US: Update on reverse settlement agreements – Amici curiae brief filed with US Court of Appeals: In re Ciprofloxacin Hydrochloride Antitrust Litigation (IP Whiteboard) (PatLit) US: An uneven debate on ‘takings’ in pharmaceutical patent law (Patent Docs) Products Aldara (Imiquimod) – US: Graceway’s injunction and Nycomed’s dismissal denied in Aldara suit (Patent Docs) Argatroban – US: Patent for Argatroban found valid, injunction issued… [read post]
10 Oct 2017, 4:12 pm
Astrazeneca Pharmaceutical LP held a leave of absence or a leave extension can constitute a reasonable accommodation under the ADA “in some circumstances”, although in that case ultimately concluded the plaintiff could not show her request for twelve additional months of leave was facially reasonable. [read post]
16 Jan 2009, 5:00 am
(IP finance) US: Medarex, Eurand and Alexion file actions against Director Dudas seeking revised patent term adjustment determinations (Patent Docs) US: Kubin panel questions motivation behind reversal in new Written Description Training Materials (Patent Docs) US: The obviousness of DNA - Federal Circuit heard oral argument for In re Kubin last week (Patent Docs) Products Antara (Fenofibrate) – US: Oscient and Ethypharm file patent infringement suit against Lupin over Antara… [read post]
10 Aug 2010, 6:10 am
Astrazeneca Pharmaceuticals LP, 585 F. [read post]
16 Jul 2010, 12:10 pm
LP v. [read post]
29 Jun 2010, 6:01 pm
(Docket Report) US: Update on reverse settlement agreements – Amici curiae brief filed with US Court of Appeals: In re Ciprofloxacin Hydrochloride Antitrust Litigation (IP Whiteboard) (PatLit) US: An uneven debate on ‘takings’ in pharmaceutical patent law (Patent Docs) Products Aldara (Imiquimod) – US: Graceway’s injunction and Nycomed’s dismissal denied in Aldara suit (Patent Docs) Argatroban – US: Patent for Argatroban found valid, injunction… [read post]
12 Jan 2010, 7:26 am
"); AstraZeneca LP v. [read post]
10 Oct 2017, 4:12 pm
Astrazeneca Pharmaceutical LP held a leave of absence or a leave extension can constitute a reasonable accommodation under the ADA “in some circumstances”, although in that case ultimately concluded the plaintiff could not show her request for twelve additional months of leave was facially reasonable. [read post]
23 Jul 2009, 3:15 am
Astrazeneca Pharmaceuticals LP), because of Bexis' firm's involvement in the litigation (although not this aspect). [read post]
26 Jan 2011, 1:31 am
In April of last year, we obtained a $520 million settlement with AstraZeneca LP and AstraZeneca Pharmaceuticals LP to resolve allegations that marketing of the anti-psychotic drug Seroquel for uses not approved as safe and effective by the FDA caused false claims to be submitted to federal health care programs. [read post]
18 Dec 2015, 9:19 am
AstraZeneca Pharm. [read post]
6 May 2017, 10:11 am
The decision Braintree v. [read post]
